. In vitro activity of MK-0826 compared to imipenem, ceftriaxone, and metronidazole against anaerobic bacteria isolated from intra-abdominal infections. In
Introduction
Many of the 4.5 million Americans bitten by animals or humans each year require either therapeutic or prophylactic antimicrobial therapy. 1, 2 Approximately 30 000 patients will visit an emergency department for care and 10 000 will be hospitalized 2 and require intravenous antimicrobial therapy. Recent studies have shown the importance of both the aerobic and anaerobic flora of the biting animal or human in the pathogenesis of more serious wound infections and their complications.
2,3
Ertapenem (MK-0826) is a new parenteral carbapenem that is highly resistant to inactivation by a wide variety of -lactamases and has been shown to have a broad spectrum of antimicrobial activity against both aerobes and anaerobes. [4] [5] [6] [7] [8] [9] [10] These studies have focused on more typical isolates, especially those associated with nosocomial infection and intra-abdominal infections, 4, 7, 8, 11 and do not evaluate the in vitro activity against the specific range of bacteria typically found in human and animal bite wound infections. To evaluate the expanded activity of ertapenem, we determined its comparative activity along with 11 other antimicrobial agents against 420 aerobic and anaerobic strains recently isolated from infected skin and soft tissue bite wounds in humans.
Materials and methods
All isolates were identified by standard criteria. [12] [13] [14] [15] [16] [17] The specific sources were: dog bites, 117; cat bites, 156; human bites, 132; and other animal bites, 15 . The numbers and species of isolates tested are given in the To ensure purity and good growth, frozen cultures of aerobic bacteria were transferred twice on trypticase soy agar (TSA) supplemented with 5% sheep blood, or chocolate agar (Hardy Diagnostics, Santa Maria, CA, USA) and anaerobic bacteria were cultured on Brucella agar supplemented with haemin, vitamin K 1 and 5% sheep blood (Anaerobe Systems, Morgan Hill, CA, USA). Susceptibility testing was performed according to NCCLS standards.
18,19 Brucella agar supplemented with haemin, vitamin K 1 and 5% laked sheep blood was the basal medium used for anaerobic species, and for Eikenella corrodens and Bergeyella zoohelcum. Mueller-Hinton agar was used for staphylococci, and Mueller-Hinton agar supplemented with 5% sheep blood was used for the remainder of the organisms.
The agar plates were inoculated with a Steers replicator (Craft Machine Inc., Chester, PA, USA). The inoculum used for aerobic bacteria was 10 4 cfu/spot, and the inoculum used for E. corrodens and anaerobic bacteria was 10 5 cfu/spot. Control plates without antimicrobial agents were inoculated before and after each set of drugcontaining plates. Plates with aerobic isolates were incubated at 35ЊC in an aerobic environment for 18-20 h and then examined. E. corrodens and streptococci were incubated in 5% CO 2 for 42-44 h, and plates with anaerobes were incubated in an anaerobic chamber (Anaerobe Systems) at 35ЊC for 48 h.
The control strains included Staphylococcus aureus ATCC 29213, Enterococcus faecalis ATCC 29212, Escherichia coli ATCC 25922, Bacteroides fragilis ATCC 25285 and Bacteroides thetaiotaomicron ATCC 29741. These strains were tested simultaneously with the appropriate plates and environments. The MIC was defined as the lowest concentration of an agent that yielded no growth, or a marked change in the appearance of growth as compared with the growth control plate.
Results
The full results of the study are noted in the 
Discussion
Previous studies 10, 11 have reported that Fusobacterium nucleatum is susceptible to р0.06 mg/L of ertapenem, as it was in our study. Of particular interest is that F. nucleatum species (MIC 50/90 1/8 mg/L) and Fusobacterium russii (MIC Ͼ 8 mg/L) of animal origin were more resistant to levofloxacin than those isolated from human bites (MIC 50/90 0.25/1 mg/L). This disparity was also seen with ciprofloxacin, but to a more modest extent of one doubling dilution, since the fusobacteria are generally more resistant to ciprofloxacin. One could speculate that this might be associated with the use of fluoroquinolones for veterinary infections as well as growth promotion. In addition, 3/12 of the F. nucleatum animal isolates were -lactamase producers, while none of the 14 human isolates produced -lactamase.
Wexler et al. 10 reported that ertapenem (MK-0826) inhibited 14 strains of Campylobacter gracilis at р0.25 mg/L. However, in our study, the only isolates tested that required у16 mg/L of ertapenem for inhibition were four of five C. gracilis and one of three Campylobacter rectus strains. The reason for this disparity is unclear, as we used the same methods, agar medium and inoculum as Wexler et al. 10 Our Campylobacter strains were also resistant to all other -lactam agents tested, but susceptible to the fluoroquinolones (levofloxacin, ciprofloxacin) and doxycycline.
As expected, oxacillin was relatively inactive against E. corrodens, EF-4a and EF-4b isolates, Neisseria spp., Moraxella spp. and Veillonella spp., and often 2-4 mg/L was required to inhibit B. zoohelcum; it also required 1-4 mg/L of oxacillin to inhibit the various Pasteurella species, making it of limited clinical value in the therapy of bite wound infections. Cefotetan had limited activity against B. zoohelcum and streptococci.
Ertapenem has an excellent broad spectrum of activity and consequently merits further evaluation as a therapeutic alternative in serious animal and human bite wound infections. 
